Cost of New PCSK9 Inhibitors May Overwhelm Patients and Payers

A new class of injectable cholesterol-lowering drugs, PCSK9 inhibitors, are good news for patients who are unresponsive to statins, but their current price. How will payers make this work? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 9/2/15)

You might also be interested in:

Are Payers Warming Up to Pricey Cholesterol Drugs? April 16, 2018
Pfizer VP Talks Value Based Reimbursement February 2, 2018
Four Barriers to Value-Based Care February 8, 2018
Amgen to Cut Price of Cholesterol Drug by 60% October 26, 2018
Regeneron, Sanofi to Cut Price of Praluent March 12, 2018
Analysis: Amgen’s Repatha Money-Back Guarantee May Fall Short April 10, 2018
Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017 January 15, 2018